We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020.
- Could you give us a brief overview of the most well known cytokines in the pathogenesis of psoriasis? (0:13)
- What have we learned about the role of IL-36 in the pathogenesis of plaque psoriasis? (1:20)
- What therapeutic agents targeting IL-36 have been developed? (3:02)
- What other molecules in the IL-1 superfamily may be useful therapeutic targets? (4:22)
Disclosures: Lluís Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Psoriasis
Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]
Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis
We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]
Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis
We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions What are the major unmet needs in the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!